- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02487797
Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation
A Randomized Double Blind Clinical Trial Comparing Oxytocin Low-dose and High-dose Regimens for Labor Augmentation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized double blind clinical trial of consenting nulliparous women in spontaneous labor who require oxytocin for labor augmentation seeks to determine whether use of a high dose oxytocin regimen improves obstetric outcomes when compared with a low dose oxytocin regimen, in a manner that is safe for both mother and neonate.
This project will include 1002 women recruited from the obstetrical service at Prentice Women's Hospital. Women will be included if they are at least 36 weeks gestation, have a singleton pregnancy, and have been diagnosed with spontaneous labor or spontaneous rupture of membranes. Women will be exposed to oxytocin for the indication of labor augmentation at the discretion of their obstetric provider.
Women will be randomized with equal probability to intervention group using a fixed allocation procedure. To maintain a double blind design, the Prentice Women's Hospital pharmacy will carry out the randomization of oxytocin solutions according to the random assignment so that neither the women or their care providers nor the investigators will know the identity of the intervention assignment. The low-dose oxytocin regimen group will receive a starting oxytocin regimen concentration rate of 2 milliunits/minute that can be increased at increments of 2 milliunits/minute, as per the discretion of their obstetric provider. The high-dose oxytocin regimen group will receive a starting oxytocin regimen concentration rate of 6 milliunits/minute that can be increased at increments of 6 milliunits/minute, as per the discretion of their obstetric provider.
Once the women are enrolled, randomized, and in receipt of their assigned interventions, further clinical management will be left to the discretion of each woman's obstetric provider.
Prior to discharge from the hospital, baseline demographic and clinical data will be obtained via chart review.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to give informed written consent
- Age 18-45 years
- Nulliparous
- Pregnant with a live singleton gestation that is equal to or greater than 36 weeks
- Diagnosed with at least 6 regular uterine contractions in an observation period of no more than 60 minutes and at least one of the following: spontaneous rupture of membranes, OR cervix greater than or equal to 3 centimeters dilated OR cervix at least 80% effaced.
- The participant's attending obstetric physician or midwife has determined that the participant needs administration of oxytocin infusion for labor augmentation. Labor augmentation will be defined as stimulation of uterine contractions when spontaneous contractions have failed to result in progressive cervical dilation of descent of fetus.
Exclusion Criteria:
- Women not meeting the above criteria
- History of prior cesarean section or uterine surgery
- Fetus in non-cephalic presentation
- Participant is undergoing labor induction (i.e. cervical ripening)
- Non-English speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High dose oxytocin regimen
The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%).
The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
|
Other Names:
Other Names:
|
Active Comparator: Low dose oxytocin regimen
The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%).
The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Delivered by Cesarean
Time Frame: At time of delivery
|
Number of participants delivered by cesarean section
|
At time of delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Labor Augmentation Duration
Time Frame: Number of hours from randomization to delivery
|
Time from randomization to delivery
|
Number of hours from randomization to delivery
|
Number of Participants With Postpartum Hemorrhage
Time Frame: From date of delivery to date of hospital discharge, an expected average of 3 days
|
Estimated blood loss greater than 500 milliliters after a vaginal delivery or greater than 1000 milliliters after a cesarean delivery
|
From date of delivery to date of hospital discharge, an expected average of 3 days
|
Number of Participants With Intrapartum Chorioamnionitis
Time Frame: From time of labor admission to time of delivery, an expected average of 24 to 48 hours
|
Fever greater than 100.4
Fahrenheit in the intrapartum period with the initiation of a therapeutic antibiotic regimen in the intrapartum period
|
From time of labor admission to time of delivery, an expected average of 24 to 48 hours
|
Number of Participants With Postpartum Endometritis
Time Frame: From time of delivery to time of hospital discharge, an expected average of 3 days
|
Fever greater than 100.4
Fahrenheit in the postpartum period with the initiation of a therapeutic antibiotic regimen in the postpartum period
|
From time of delivery to time of hospital discharge, an expected average of 3 days
|
Number of Participants Whose Offspring Experiences a Perinatal Death
Time Frame: Study enrollment to delivery (if intrapartum stillbirth) or 28 days of life (if liveborn)
|
Perinatal death includes intrapartum stillbirth and neonatal death
|
Study enrollment to delivery (if intrapartum stillbirth) or 28 days of life (if liveborn)
|
Number of Participants With Umbilical Cord Acidemia
Time Frame: At time of delivery
|
Umbilical cord arterial blood pH less than 7.0 or base deficit greater than 12 mmol/L; or cord venous blood pH less than 7.0 or base deficit greater than 12 mmol/L when umbilical artery values are not available
|
At time of delivery
|
Neonatal Apgar Score of Less Than 3 at 5 Minutes of Life
Time Frame: Delivery through 5 minutes of life
|
Number of participants with neonates with Apgar score of less than 3 at 5 minutes of life.
This is using a Apgar scale which ranges from minimum total score of 0 and maximum total score of 10, with higher score representing a better outcome.
|
Delivery through 5 minutes of life
|
Admission to Neonatal Intensive Care Unit
Time Frame: Delivery to 28 days of life
|
Number of participants whose neonates are admitted to Neonatal Intensive Care Unit
|
Delivery to 28 days of life
|
Number of Participants Whose Neonates Experience a Composite of Severe Neonatal Morbidity and Perinatal Mortality
Time Frame: Delivery to 28 days of life
|
Neonatal composite morbidity will be defined as occurrence of any of the following: perinatal death, severe, respiratory distress, major birth injury, encephalopathy, seizure, need for hypothermic treatment, or sepsis
|
Delivery to 28 days of life
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Moeun Son, MD, MSCI, Northwestern University
- Principal Investigator: Alan Peaceman, MD, Northwestern University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00201148
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dystocia
-
Karabuk UniversityRecruiting
-
Clemens TempferCompletedShoulder DystociaGermany
-
Christiana Care Health ServicesCompleted
-
Ain Shams Maternity HospitalCompletedCervical DystociaEgypt
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); The Ottawa Hospital; The Physicians... and other collaboratorsTerminated
-
Ain Shams UniversityCompletedFailed Induction | Cervical DystociaEgypt
-
G. d'Annunzio UniversityClaudio Crescini, MD Humanitas Milan Italy; Federico Prefumo, Istituto Giannina... and other collaboratorsCompletedBirth Disorder | Shoulder Dystocia - DeliveredItaly
-
The Baruch Padeh Medical Center, PoriyaUnknownShoulder Dystocia | Induction of Labor | Macrosomia | Expectant Management
Clinical Trials on Oxytocin
-
Hillel Yaffe Medical CenterUnknownCervix; Insufficient Dilatation in LaborIsrael
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
University of Electronic Science and Technology...Completed
-
GlaxoSmithKlineCompletedPostpartum HemorrhageUnited Kingdom
-
University of Electronic Science and Technology...Recruiting
-
GlaxoSmithKlineMonash University; InVentiv CliniqueTerminatedPostpartum HemorrhageAustralia, United Kingdom
-
University Hospital, ToulouseCompleted
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
Washington University School of MedicineUniversity of MichiganRecruiting
-
University of NebraskaNot yet recruiting